New research highlights the benefits of combining lutetium PSMA 617 with standard treatments, showing improved outcomes for prostate cancer patients.
Scott Tagawa, MD
Advertisement
Articles by Scott Tagawa, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Higher-Dose Semaglutide Achieves Significant Weight Reduction in Adults with Obesity
2
FDA Removes Black Box Warning From Hormone Therapies for Menopause
3
Boehringer Ingelheim Advances Cardio-Kidney-Metabolic Research Through Integrated Therapeutic Development
4
The Average Health Insurance Premium Now Costs $27k Per Year for a Family
5
